|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1400 Crystal Drive |
Address2 | Suite 300 |
| City | Arlington |
State | VA |
Zip Code | 22202 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 46803-12
|
||||||||
|
6. House ID# 343580000
|
||||||||
| TYPE OF REPORT | 8. Year | 2020 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Dorothy Farrell |
Date | 4/16/2020 5:42:19 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
HOUSE/SENATE - FY21 NIH Funding Recommendation
AACP signed onto a letter by the Ad Hoc Committee For Medical Research recommending $44.7 billion for the NIH, a $3 billion (7.2%) increase over the FY 2020 program level. This funding level includes the full $404 million NIH is scheduled to receive in FY 2021 from the Innovation Account established in the 21st Century Cures Act for specific programs.
HOUSE/SENATE - Friends of VA FY21 Funding Request
AACP endorsed the FOVA FY 21 recommendation for the VA research program asking for $860 million for the VA Medical and Prosthetic Research program in FY 2021, a $60 million increase over the appropriated level in FY 2020.
HOUSE/SENATE - FY21 Funding Request
AACP signed onto a Friends of NCHS Fiscal Year 2020 recommending in support of the National Center on Health Statistics (NCHS) recommending an appropriation of at least $189 million for the agency.
HOUSE/SENATE - ECHO FY21 Funding Request
AACP signed onto to a letter requesting appropriations of $180 million in funding for the Environmental influences on Child Health Outcomes (ECHO) program in FY21.
HOUSE - Friends of AHRQ Funding
AACP signed onto a letter led by the Friends of AHRQ coalition requesting $471 million appropriation for the Agency for Healthcare Research and Quality (AHRQ) for FY21.
HOUSE - Giffords Coalition on Gun Safety
AACP signed onto a letter asking for $50 million in funding to be shared by the CDC and NIH to conduct public health research into firearm morbidity and mortality prevention.
House/Senate - COVID-19 Response
AACP signed onto a letter led by the American Society for Microbiology, Association of American Universities, Association of Public Health Laboratories, and Trust for Americas Health calling on appropriators to review the response to COVID-19 pandemic.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jasey |
Cardenas |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code GOV
16. Specific lobbying issues
SENATE - White House ONDCP HIDTA DFC
AACP signed onto a letter requesting that the HIDTA and DFC programs remain at the office of the National Drug Control Policy.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jasey |
Cardenas |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
NIH/FDA - CAMT COVID-19
AACP signed onto a letter led by the Coalition to Advance Maternal Therapeutics (CAMT) urging NIH and FDA to ensure that pregnant women and lactating women are included in all research for the development of vaccines and therapeutics related to COVID-19.
White House - Fetal Tissue research related to COVID-19
AACP signed onto a letter urging President Trump to lift the restrictions on federally funded research using human fetal tissue immediately.
House/Senate/White House - FASHP COVID-19
AACP signed onto a letter led by the Federation of Associations of Schools of the Health Professions (FASHP) urging the House and Senate to consider the unique economic and educational needs of the nations health professions schools and students, and the associations that represent them, in any federal legislative or stimulus package.
CMS - Comments on Proposed Rule
AACP signed onto comments led by the Pharmacy Quality Alliance (PQA) to CMS on proposed rule for Medicare and Medicaid Programs: Contract Year 2021 and 2022 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicaid Program, Medicare Cost Plan Program, and Programs of All-inclusive Care for the Elderly.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, White House Office, Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Natl Institutes of Health (NIH)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jasey |
Cardenas |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
CMS - PROVIDER STATUS FOR PHARMACISTS
Signed onto comment letter led by American Pharmacists Association to CMS Secretary Verma requesting that pharmacists gain provider status during the duration of the public health crisis of COVID-19.
17. House(s) of Congress and Federal agencies Check if None
Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jasey |
Cardenas |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |